Middle East tensions are stoking volatility; a low-beta screen spotlights Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy.

Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market.

LQDA, NEXA and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 13th, 2026.

HCSG, NUE, NEXA, LQDA and NKSH have been added to the Zacks Rank #1 (Strong Buy) List on May 13th, 2026.

Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.

Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but further market share gains are likely capped by entrenched competitors and limited product differentiation. At a near $5 billion market cap and 9x run-rate revenue, the current valuation assumes sustained momentum and peak Yutrepia sales north of $1.2 billion, which appears optimistic.

Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript

Liquidia NASDAQ: LQDA reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.